Altis Biologics: From Labs to Riches? Update

Author :

Diran Soumonni & Stephanie Townsend

Pages :

19 pages

Product Type :

Case

Reference # :

WBS-2017-9

Teaching Note :

not available

Institute:

Wits Business School - University of the Witwatersrand

Setting:

South Africa

Year:

2017

Keywords:

Entrepreneurship

Summary/Abstract:

In January 2017, Dr Nicolaas Duneas, founder and chief executive officer of Altis Biologics – a small, South African-based biotechnology company specialising in bone regeneration – was beginning to wonder whether he had chosen the right strategy for commercialising his technology. Bone regeneration was necessary when broken or damaged bones could not heal themselves and surgeons had to use a catalyst to enable the process. In the early 2000s, Duneas had developed a catalyst derived from humanised porcine bone, which provided a less expensive, more accessible and more scalable alternative to those derived from human bone and synthetic sources. (See Exhibit 1 and Exhibit 2.)